141 related articles for article (PubMed ID: 7579552)
21. Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.
Pectasides D; Yianniotis H; Alevizakos N; Bafaloukos D; Barbounis V; Varthalitis J; Dimitriadis M; Athanassiou A
Br J Cancer; 1989 Oct; 60(4):627-9. PubMed ID: 2803936
[TBL] [Abstract][Full Text] [Related]
22. Dacarbazine, nimustine hydrochloride, cisplatin and tamoxifen combination chemotherapy for advanced malignant melanoma.
Yamazaki N; Yamamoto A; Wada T; Ishikawa M
J Dermatol; 1999 Aug; 26(8):489-93. PubMed ID: 10487002
[TBL] [Abstract][Full Text] [Related]
23. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
25. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
26. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.
Eigentler TK; Caroli UM; Radny P; Garbe C
Lancet Oncol; 2003 Dec; 4(12):748-59. PubMed ID: 14662431
[TBL] [Abstract][Full Text] [Related]
27. The treatment of metastatic melanoma with chemotherapy and biologics.
Atkins MB
Curr Opin Oncol; 1997 Mar; 9(2):205-13. PubMed ID: 9161801
[TBL] [Abstract][Full Text] [Related]
28. Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma.
Kerin MJ; Gillen P; Monson JR; Wilkie J; Keane FB; Tanner WA
Eur J Surg Oncol; 1995 Oct; 21(5):548-50. PubMed ID: 7589604
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Feun L; Marini A; Moffat F; Savaraj N; Hurley J; Mazumder A
Cancer Invest; 2005; 23(1):3-8. PubMed ID: 15779861
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy of malignant melanoma].
Ishihara K; Yamazaki N; Asano K
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1287-92. PubMed ID: 7688498
[TBL] [Abstract][Full Text] [Related]
32. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
33. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
36. Systemic treatment of metastatic melanoma with chemotherapy.
Green RJ; Schuchter LM
Hematol Oncol Clin North Am; 1998 Aug; 12(4):863-75, viii. PubMed ID: 9759584
[TBL] [Abstract][Full Text] [Related]
37. Use of tamoxifen in the treatment of malignant melanoma.
Lens MB; Reiman T; Husain AF
Cancer; 2003 Oct; 98(7):1355-61. PubMed ID: 14508820
[TBL] [Abstract][Full Text] [Related]
38. [Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Akimov MA; Gel'fond ML; Gershanovich ML; Barchuk AS
Vopr Onkol; 2003; 49(3):312-5. PubMed ID: 12926212
[TBL] [Abstract][Full Text] [Related]
39. Management of metastatic cutaneous melanoma.
Buzaid AC
Oncology (Williston Park); 2004 Oct; 18(11):1443-50; discussion 1457-9. PubMed ID: 15609471
[TBL] [Abstract][Full Text] [Related]
40. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
